ArticleCell death & disease2013

Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.

R Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.